next generation semaglutide Novo Nordisk's next-gen obesity drug outperforms Wegovy in late-stage diabetes trial If semaglutide does not work

Bringing Psoriasis Into the Light

Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity

Combination therapy is not for everyone

A mere disclaimer that something is for research use only when the evidence suggests that the chemical isnt just being used for research would probably not be particularly persuasive from a legal standpoint, says Patti Zettler, an expert on food and drug law and the John W

Plaintiffs pursuing GLP-1 vision loss lawsuits allege that manufacturers failed to adequately warn patients and prescribing physicians about reports of NAION and other potentially irreversible eye complications associated with semaglutide medications

1 reason for absenteeism at work, and one of the leading causes of suicide," Rasgon said